FDA 483 - B. Braun Medical Inc. - November 22, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of B. Braun Medical Inc. in Daytona Beach, FL, a sterile drug manufacturer, revealed significant deficiencies across quality control, production, and laboratory operations. The firm failed to adequately investigate product discrepancies, distributed unreleased products, and exhibited poor adherence to established procedures for visual inspections, sterility testing, and laboratory data integrity. These issues indicate a lack of robust quality oversight and could impact the quality and safety of their sterile drug products.
ID · 1fd1fc7b-4985-4e05-9cf7-94317763ef8f